Keymed Biosciences
Chengdu
About Keymed Biosciences
Keymed Biosciences develops innovative monoclonal antibody drugs and other therapeutic protein drugs for cancer, autoimmune diseases, and infectious diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Total funding: $108.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: hkg:2162
- Website: en.keymedbio.com
- Phone: 028-88610620
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/keymed-biosciences-76533 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.